Management

Mr. Young is a US-based long-time executive in the biopharmaceuticals industry.  He is the former President and CEO of Osteologix, Inc, a global biopharmaceutical company, which is currently based in Ireland.  He joined Osteologix in May 2007 and led the multinational company’s efforts to develop a novel therapy for osteoporosis which resulted in a global licensing deal with Servier Laboratories, a private French pharmaceutical company.  He remains on the Board of Directors for Osteologix Holdings Ltd.

Prior to joining Osteologix, Mr. Young held a number of senior executive positions with publicly traded biotechnology companies. From 2004-2007 he was with Insmed Inc., where he served as executive vice president and chief business officer. While at Insmed, Mr. Young led the successful launch and commercialization of a novel biologic growth hormone therapy and assisted the company in raising over $100 million to further the company objectives and expand the drug’s research pipeline to other diseases. Previously, Mr. Young served as president and chief operating officer at several biotechnology companies in the San Francisco Bay area. While serving as a Vice President at Neurex Pharmaceuticals, Mr. Young was a key member of the negotiating team that successfully sold Neurex to Elan for over $700 million.

Dr. Harper has served as Chief Scientific Officer of AmpliPhi Biosciences since the January 2011 acquisition of Biocontrol Ltd. by Targeted Genetics Corporation. Dr. Harper founded Biocontrol in 1997.  He previously served as leader of the herpes virus research group in the Department of Virology at St. Bartholomew’s Medical School, joining the faculty in 1991 as a Lecturer in Molecular Virology.  Dr. Harper received his B.Sc. in microbiology and virology at the University of Warwick and Ph.D. at the University of Newcastle-upon-Tyne studying viral genetics.  He he carried out post-doctoral work at St. Bartholomew’s Medical School in London and at the University of Iowa.

Professor Enright has served as Research Director of AmpliPhi Biosciences since our January 2011 acquisition of Biocontrol Ltd.  He joined Biocontrol as Research Director in May 2010 from his position as Professor of Molecular Epidemiology at Imperial College Medical School, a post he held since 2007.  Professor Enright first established his own research group at the University of Bath in 2000, after winning a Royal Society University Research Fellowship. His research focused on the study of the epidemiology and evolution of methicillin-resistant S. aureus (MRSA) in projects funded by the Wellcome Trust, UK Medical Research Council and the Department of Health.

Professor Enright has published more than 100 scientific articles in the areas of bacteriology, population biology and infectious disease. He received his Ph.D. at Aberdeen University Medical School in Scotland, based upon his research on the genetic characterization of gram-negative pathogens followed by post-doctoral work at Oxford and Sussex Universities in the laboratories of Professor Brian Spratt CBE, FRS.

Dr. McConville has served as Research Director of AmpliPhi Biosciences since our January 2011 acquisition of Biocontrol Ltd. Dr. McConville joined Biocontrol as Development Manager in 2007. Prior to joining Biocontrol, Dr. McConville gained more than three decades of experience working in the contract research organization industry at Inveresk Research/Charles River Laboratories where he managed laboratory groups offering services in genotoxicity, molecular biology and microbiology to the pharmaceutical and animal health sectors.  Dr. McConville received a B.Sc. in Microbiology at University College, Cardiff and a Ph.D. at the University of Reading studying the genetics of haem biosynthesis in Escherichia coli.